Amundi Has $49.02 Million Holdings in Incyte Co. (NASDAQ:INCY)

Amundi raised its holdings in shares of Incyte Co. (NASDAQ:INCY) by 28.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 670,350 shares of the biopharmaceutical company’s stock after buying an additional 150,431 shares during the quarter. Amundi owned about 0.35% of Incyte worth $49,023,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Andra AP fonden increased its position in shares of Incyte by 7.9% during the fourth quarter. Andra AP fonden now owns 212,500 shares of the biopharmaceutical company’s stock valued at $14,677,000 after purchasing an additional 15,500 shares during the period. Edgestream Partners L.P. increased its position in shares of Incyte by 173.0% during the fourth quarter. Edgestream Partners L.P. now owns 61,174 shares of the biopharmaceutical company’s stock valued at $4,225,000 after purchasing an additional 38,766 shares during the period. Ashton Thomas Private Wealth LLC bought a new stake in shares of Incyte during the fourth quarter valued at approximately $717,000. Candriam S.C.A. increased its position in shares of Incyte by 27.8% during the fourth quarter. Candriam S.C.A. now owns 1,034,652 shares of the biopharmaceutical company’s stock valued at $71,463,000 after purchasing an additional 224,919 shares during the period. Finally, Inceptionr LLC bought a new stake in shares of Incyte during the fourth quarter valued at approximately $844,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Incyte

In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of the stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $74.07, for a total value of $1,042,090.83. Following the transaction, the executive vice president now owns 25,848 shares of the company’s stock, valued at approximately $1,914,561.36. This represents a 35.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Steven H. Stein sold 12,352 shares of the stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the completion of the sale, the executive vice president now owns 66,967 shares of the company’s stock, valued at $4,867,831.23. This trade represents a 15.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,320 shares of company stock valued at $2,072,849. 17.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have weighed in on INCY. William Blair reiterated an “outperform” rating on shares of Incyte in a research report on Friday, December 13th. UBS Group began coverage on Incyte in a research report on Tuesday, December 17th. They issued a “neutral” rating and a $77.00 price target on the stock. Royal Bank of Canada lowered their price target on Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a research report on Tuesday, February 11th. Citigroup reduced their price objective on Incyte from $97.00 to $88.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. Finally, Wells Fargo & Company boosted their price objective on Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $75.25.

Incyte Trading Down 0.5 %

NASDAQ:INCY opened at $67.73 on Thursday. Incyte Co. has a 1-year low of $50.35 and a 1-year high of $83.95. The business’s 50-day moving average price is $71.82 and its two-hundred day moving average price is $70.27. The company has a current ratio of 1.97, a quick ratio of 1.94 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $13.11 billion, a price-to-earnings ratio of 250.86, a PEG ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last released its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, equities analysts expect that Incyte Co. will post 4.86 earnings per share for the current year.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.